BioSci_Covid_Alliances

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R	S	T	U	V	W	X	Y	Z	AA	AB	AC	AD	AE	AF	AG	AH	AI	AJ	AK	AL	AM	AN	AO
1	Deal Date	R&D	Client	Deal Types	Stages	Deal Subject	Deal Link	Size ($M)	Equity ($M)	Maximum Share (%)	Contracts	PRs	Deal Source	Exclusivity	Diseases	Indications	Technologies	Sub Technologies	Territory	Compound Name	MOA Category	Mechanism of Action	Molecular Target	Drug Mode of Action	Upfront Cash ($M)	Upfront Equity ($M)	Contingent Equity ($M)	R&D Support ($M)	FTE Rate ($M)	Loan ($M)	Dev / Reg Milestones ($M)	Other Milestones ($M)	Total Precommercial Payments ($M)	Sales Milestones ($M)	Deal Size ($M)	Maximum Royalty (%)	Marketing Fee (%)	Transfer Price (%)	Manufacture Cost + (%)	Profit Split (%)	Financial Term Explanations

2	10/2020	AgeX Therapeutics	ImStem Biotechnology	Sublicense	Preclinical	IMS001 cell therapy candidate for COVID-19 and acute respiratory distress syndrome	Link					Yes	PR	Non-exclusive	Infectious-Viral, Respiratory	Coronavirus, Other Respiratory	Cell Therapy - Stem Cells/Factors
3	10/2020	Molecular Partners	Novartis	Equity, License, Option	Preclinical	MP0420 and MP0423 DARPin therapeutics for prevent and treat COVID-19	Link	231.00				Yes	PR		Infectious-Viral	Coronavirus									22.00	44.00									231.00	22.00					CHF 20 million (US$22M) \| CHF 40 million (US$44M) worth of ordinary shares, at a price of CHF 23 (US$25)/share, representing 6% equity stake \| CHF 150 million (US$165M), upon Novartis exercising the option to both therapeutic candidates
4	10/2020	Global Coalition for Adaptive Research	Eisai, Amgen	Research		Evaluation of apremilast and eritoran in REMAP-COVID clinical study	Link					Yes	PR		Infectious-Viral	Coronavirus
5	10/2020	Histogen	Amerimmune	Co-Development, License, Option	Preclinical	Emricasan pan-caspase inhibitor to treat COVID-19	Link					Yes	PR		Infectious-Viral	Coronavirus	Synthetics	Small Molecule
6	10/2020	George Mason University	Targeted Pharmaceutical	Research	Preclinical	Preclinical evaluation of ARDS-003 to prevent & treat COVID-19	Link					Yes	PR		Infectious-Viral	Coronavirus
7	10/2020	Infectious Disease Research Institute	Amyris	License		RNA vaccine platform to develop COVID-19 vaccine, plus three additional indications	Link					Yes	PR		Infectious-Viral, Unlimited	Coronavirus	Vaccines
8	10/2020	ADial Pharmaceuticals	Todos Medical	Distribution, License	Diagnostic	COVID-19 point of care rapid test devices	Link					Yes	PR	Non-exclusive	Infectious-Viral	Coronavirus	Diagnostics
9	10/2020	ADial Pharmaceuticals	Avalon GloboCare	Distribution, License	Diagnostic	COVID-19 point of care rapid test devices	Link					Yes	PR	Non-exclusive	Infectious-Viral	Coronavirus	Diagnostics		Worldwide
10	10/2020	Atea Pharmaceuticals	Roche	Co-Development, License	Phase II	AT-527 oral direct-acting antiviral to treat COVID-19 ex-US	Link	1,000.00			Yes	Yes	SEC Redacted	Exclusive	Infectious-Viral	Coronavirus	Synthetics	Small Molecule	Africa, Asia, Europe, Middle East, NAFTA, South America	AT-527	Antiviral		2019-nCoV (SARS-CoV-2) (COVID-19)		350.00						330.00		680.00	320.00	1,000.00						low double-digit to mid-twenties royalties, per Atea's IPO prospectus
11	10/2020	Samsung Biologics	DiNonA	CSO		Services to support development of DNP-019 antibody therapy. for COVID-19	Link					Yes	PR		Infectious-Viral	Coronavirus	Monoclonals			DNP-019	Antibody		2019-nCoV (SARS-CoV-2) (COVID-19)
12	10/2020	McMaster University	SQI Diagnostics	Research	Diagnostic	Technology to measure severity of COVID-19	Link					Yes	PR		Infectious-Viral	Coronavirus	Diagnostics
13	10/2020	Nature Technology Corporation	Aegis Life	License		Nanoplasmid plasmid DNA technology and manufacturing platform for SARS-CoV-2 vaccine	Link					Yes	PR		Infectious-Viral	Coronavirus	Vaccines
14	10/2020	Entos Pharmaceuticals	Aegis Life	License		Spin out of Aegis Life to develop SARS-CoV-2 vaccine using Entos Fusogenix technology	Link					Yes	PR		Infectious-Viral	Coronavirus	Vaccines
15	10/2020	TScan Therapeutics	Poseida Therapeutics	License, Research	Discovery	Evaluation of allogeneic T Cell receptor therapies to treat COVID-19	Link					Yes	PR		Infectious-Viral	Coronavirus	Cell Therapy - Stem Cells/Factors
16	10/2020	Lactiga, Mount Sinai Health System	NIH	Research	Preclinical	NIH funding to advance preclinical research of LCTG-001 as potential treatment for COVID-19	Link					Yes	PR		Infectious-Viral	Coronavirus				LCTG-001	Antiviral		2019-nCoV (SARS-CoV-2) (COVID-19)
17	10/2020	Yokohama City University, National Center for Global Health and Medicine, KAN Research Institute, Nagasaki University	Eisai	Research	Preclinical	Development of therapeutics for COVID-19, including preclinical evaluation of eritoran and E6011	Link					Yes	PR		Infectious-Viral	Coronavirus	Monoclonals, Synthetics	Small Molecule
18	10/2020	University of Houston	AuraVax Therapeutics	License, Option		IP covering intranasal vaccine technology for development of COVID-19 vaccine	Link					Yes	PR		Infectious-Viral, Respiratory	Coronavirus	Drug Delivery, Vaccines	Nasal
19	10/2020	AstraZeneca	Department of Health and Human Services, BARDA	Development, Supply	Phase III	AZD7442 long-acting antibody combination to treat COVID-19	Link	486.00				Yes	PR		Infectious-Viral	Coronavirus	Monoclonals			AZD7442, AZD-8895 + AZD-1061	Antiviral		2019-nCoV (SARS-CoV-2) (COVID-19)												486.00
20	10/2020	Rentschler Biopharma	BioNTech	Supply	Phase III	cGMP manufacturing services for mRNA-based vaccine candidate against SARS-CoV-2	Link					Yes	PR		Infectious-Viral	Coronavirus	Vaccines
21	10/2020	Yale	IsoPlexis	Research	Diagnostic	COVID-19 immune profiling biomarkers	Link					Yes	PR		Infectious-Viral	Coronavirus	Diagnostics
22	10/2020	Cobra Biologics	Scancell	Supply	Preclinical	Production of plasmid to generate DNA vaccine against SARS-CoV-2	Link					Yes	PR		Infectious-Viral	Coronavirus	Vaccines
23	10/2020	FibroGenesis	R4D Biotech	License	Preclinical	PneumoBlast cell therapy to treat acute respiratory distress syndrome in COVID-19 patients	Link					Yes	PR		Infectious-Viral, Respiratory	Coronavirus, Other Respiratory	Cell Therapy - Stem Cells/Factors		South America
24	09/2020	Thermo Fisher Scientific	Humanigen	Supply	Phase III	Expanded manufacturing capacity for COVID-19 therapeutic candidate lenzilumab	Link					Yes	PR		Infectious-Viral	Coronavirus	Monoclonals
25	09/2020	IriSys	TFF Pharmaceuticals	Supply		Inhalable lung medication with potential to treat COVID-19 and invasive pulmonary aspergillosis	Link					Yes	PR		Infectious-Viral, Respiratory	Coronavirus	Drug Delivery	Other
26	09/2020	Clene Nanomedicine	Tottenham Acquisition, Chelsea Worldwide	Acquisition	Phase III	Reverse merger agreement, combined public company to be named Clene Inc	Link					Yes	PR		Central Nervous System, Infectious-Viral	Alzheimer's Disease, Coronavirus, Multiple Sclerosis, Parkinson's Disease
27	09/2020	Purdue University	PhysIQ	Research		Algorithms to detect early signs of COVID-19 from biometric smartwatch data	Link					Yes	PR		Infectious-Viral	Coronavirus
28	09/2020	BioSig Technologies, ViralClear Pharmaceuticals	Sorrento Therapeutics	Research		Evaluation of small molecule and antibody combination therapies against COVID-19	Link					Yes	PR		Infectious-Viral	Coronavirus	Monoclonals, Synthetics
29	09/2020	ABEC	Serum Institute of India	Supply		Manufacture of NVX-CoV2373 COVID-19 vaccine candidate	Link					Yes	PR		Infectious-Viral	Coronavirus	Vaccines			COVID-19 vaccine, NVX-CoV2373	Vaccine	Protein Subunit	2019-nCoV (SARS-CoV-2) (COVID-19)
30	09/2020	Bachem	NeuroRx, Relief Therapeutics	Supply		Manufacture of RLF-100 (aviptadil) drug substance for COVID-19 infection with respiratory failure	Link					Yes	PR		Infectious-Viral, Respiratory	Coronavirus, Other Respiratory	Peptides			Invicorp, aviptadil, RLF-100	Peptide Hormone	vasoactive intestinal peptide receptor agonists
31	09/2020	Lumen Bioscience	US Army Medical Research and Development Command	Research		$4M grant to develop nanobody-based Covid-19 therapeutic	Link	4.00				Yes	PR		Infectious-Viral	Coronavirus	Monoclonals																		4.00
32	09/2020	Grand River Aseptic Manufacturing	Johnson & Johnson, Janssen	Supply		Technical transfer and fill and finish manufacture of SARS-CoV-2 vaccine candidate	Link					Yes	PR		Infectious-Viral	Coronavirus	Vaccines
33	09/2020	Endo International, Par Sterile Products	Novavax	Supply		Fill-finish manufacturing services for NVX-CoV2373 COVID-19 vaccine candidate	Link					Yes	PR		Infectious-Viral	Coronavirus	Vaccines			COVID-19 vaccine, NVX-CoV2373	Vaccine	Protein Subunit	2019-nCoV (SARS-CoV-2) (COVID-19)
34	09/2020	Novartis	BioNTech	Asset Purchase		GMP certified manufacturing facility in Germany to expand COVID-19 vaccine production capacity	Link					Yes	PR		Infectious-Viral	Coronavirus	Vaccines
35	09/2020	List Biological Laboratories	BetterLife Pharma	Supply	Phase II	Manufacture of AP-003 interferon alpha 2b to treat COVID-19	Link					Yes	PR		Infectious-Viral	Coronavirus	Recombinant DNA			AP-003	Antiviral		interferon alpha 2b (IFNa2b)	Inhibitor
36	09/2020	Zymeworks	ImmunoPrecise Antibodies	License, Research		Azymetric and EFECT platforms to develop SARS-CoV-2 antibody against COVID-19	Link					Yes	PR		Infectious-Viral	Coronavirus	Monoclonals
37	09/2020	Lonza	Humanigen	Supply	Phase III	Manufacture of Lenzilumab COVID-19 candidate	Link					Yes	PR		Infectious-Viral	Coronavirus	Monoclonals			lenzilumab, KB003	Antiviral		colony stimulating factor 2 receptor, alpha, low-affinity (granulocyte-macrophage) (CSF2RA) (GMR) (CD116) (GM-CSF-R-alpha)
38	09/2020	IncellDx	MD Biosciences	License	Diagnostic	COVID-19/cytokine storm cytokine panel and CCR5 receptor occupancy in the US and EU	Link					Yes	PR		Infectious-Viral	Coronavirus	Diagnostics		Europe, NAFTA
39	09/2020	Dynavax Technologies	Valneva	Supply		CpG 1018 adjuvant for use in VLA2001 SARS-CoV-2 vaccine candidate	Link					Yes	PR		Infectious-Viral	Coronavirus	Adjuvant, Vaccines			VLA2001	Vaccine	Inactivated	2019-nCoV (SARS-CoV-2) (COVID-19)
40	09/2020	HiFiBiO	ABL Bio	Co-Development, License	Preclinical	HFB30132A SARS-CoV-2 neutralizing antibody for COVID-19	Link					Yes	PR		Infectious-Viral	Coronavirus	Monoclonals			HFB30132A, HFB-3013	Antiviral		2019-nCoV (SARS-CoV-2) (COVID-19)	Inhibitor
41	09/2020	Vaxess Technologies	Medigen Vaccine Biologics	Development, License	Formulation	MIMIX patch system to deliver COVID-19 and quadrivalent seasonal influenza vaccine	Link					Yes	PR		Infectious-Viral	Coronavirus, Influenza	Drug Delivery, Vaccines	Transdermal
42	09/2020	Arctoris	Syntekabio	Letter of Intent, License, Research	Discovery	AI-driven drug discovery to assess small molecule therapeutics for COVID-19	Link					Yes	PR		Infectious-Viral	Coronavirus	Screening, Synthetics	Small Molecule
43	09/2020	Aditx Therapeutics	Salveo Diagnostics	License	Diagnostic	AditxtScore Platform for COVID-19 to detect antibodies against SARS-CoV-2 antigens	Link					Yes	PR		Infectious-Viral	Coronavirus	Diagnostics
44	09/2020	Thermo Fisher Scientific	Inovio Pharmaceuticals	Letter of Intent, Supply		Manufacture of INO-4800 DNA COVID-19 vaccine candidate	Link					Yes	PR		Infectious-Viral	Coronavirus	Vaccines			INO-4800	Vaccine	DNA	2019-nCoV (SARS-CoV-2) (COVID-19)
45	09/2020	Relation Therapeutics	Bill & Melinda Gates Foundation	Research		Grant to support machine learning to identify repurposed drug combinations for COVID-19	Link	1.30				Yes	PR		Infectious-Viral	Coronavirus																			1.30
46	09/2020	MicroGEM	NIH	Development	Diagnostic	Funding to support development of fast-track rapid, no-lab COVID-19 saliva test	Link	40.90				Yes	PR		Infectious-Viral	Coronavirus, Influenza	Diagnostics																		40.90
47	08/2020	Serum Institute of India	GAVI the Vaccine Alliance, Bill & Melinda Gates Foundation	Supply		100 million doses of COVID-19 vaccines for low-income countries, expanded to 200 million doses	Link	300.00				Yes	PR		Infectious-Viral	Coronavirus	Vaccines																		300.00
48	08/2020	Fio	Relay Medical	Joint Venture	Diagnostic, Device	Joint venture to accelerate adaption of Fionet data-and-device platform for COVID-19 testing	Link					Yes	PR		Infectious-Viral	Coronavirus	Diagnostics
49	08/2020	AllStar Health Brands	TPT Global Tech	Distribution	Diagnostic	QuikLAB Rapid Covid-19 Testing Lab Modules	Link					Yes	PR	Non-exclusive	Infectious-Viral	Coronavirus	Diagnostics		NAFTA, South America
50	08/2020	NOWDiagnostics	Department of Health and Human Services, BARDA	Development	Diagnostic	ADEXUSDx COVID-19 rapid antibody test	Link					Yes	PR		Infectious-Viral	Coronavirus	Diagnostics
51	08/2020	Humanetics	Pharmaceutics International	Research		Clinical evaluation of BIO 300 in COVID-19 patients	Link					Yes	PR		Infectious-Viral, Respiratory	Coronavirus				BIO 300, genistein nanoparticle			apoptosis, protein tyrosine kinase (PTK)	Inhibitor
52	08/2020	IriSys	Qualigen	Supply	Preclinical	Manufacture of AS1411 drug product to treat viral diseases including COVID-19	Link					Yes	PR		Infectious-Viral	Coronavirus				AS1411, ACT-GRO-777, AGRO-100	DNA/RNA Disruption		apoptosis	Stimulant
53	08/2020	Sugentech	Avellino Labs	Distribution, License	Diagnostic	COVID-19 rapid diagnostic serology test and ELISA to detect COVID-19 antibodies	Link					Yes	PR		Infectious-Viral	Coronavirus	Diagnostics
54	08/2020	Sinovac Biotech	Bio Farma	License, Supply	Phase III	CoronaVac inactivated vaccine candidate against COVID-19	Link					Yes	PR		Infectious-Viral	Coronavirus	Vaccines			CoronaVac	Vaccine	Inactivated	2019-nCoV (SARS-CoV-2) (COVID-19)
55	08/2020	Harvard	AbbVie	Research		Emergent viral disease research with focus on coronavirus and viruses that lead to hemorrhagic fever	Link	30.00				Yes	PR		Infectious-Viral	Coronavirus	Monoclonals, Synthetics	Small Molecule										30.00							30.00
56	08/2020	NantKwest	ImmunityBio	Co-Development, License		COVID-19 therapeutics and vaccine candidates	Link					Yes	PR		Infectious-Viral	Coronavirus	Cell Therapy - Stem Cells/Factors, Vaccines
57	08/2020	CytoSorbents	Terumo	Distribution, License	Device	CytoSorb extracorporeal cytokine adsorber for use in critically ill COVID-19 patients	Link					Yes	PR		Infectious-Viral	Coronavirus	Device
58	08/2020	Avid Bioservices	Oragenics	Supply		CDMO services to support development of Terra CoV-2 vaccine candidate for COVID-19	Link					Yes	PR		Infectious-Viral	Coronavirus	Vaccines
59	08/2020	Regeneron Pharmaceuticals	Roche	Co-Development, Distribution	Phase III	Distribution of REGN-COV2 anti-viral antibody cocktail to prevent and treat COVID-19 outside the US	Link					Yes	PR		Infectious-Viral	Coronavirus	Monoclonals			REGN-COV2, REGN-10933+ REGN-10987	Antiviral		2019-nCoV (SARS-CoV-2) (COVID-19)																		Companies will jointly fund and execute certain ongoing clinical studies. Roche will be responsible for distribution outside the U.S.
60	08/2020	Utrecht University, Harbour BioMed, Erasmus	Viroclinics Biosciences, Kiadis Pharma	Development		Monoclonal antibody and natural killer cell combination therapy to treat COVID-19	Link					Yes	PR		Infectious-Viral	Coronavirus	Cell Therapy - Stem Cells/Factors, Monoclonals
61	08/2020	BioSymetrics	Johnson & Johnson, Janssen	Research		Contingent-AI machine learning to predict onset and severity of COVID-19 in different populations	Link					Yes	PR		Infectious-Viral	Coronavirus
62	08/2020	Aragen Bioscience	NorthStar Medical Radioisotopes, Monopar Therapeutics	CRO		CRO services to select uPRIT lead candidate to advance into IND-enabling development for COVID-19	Link					Yes	PR		Infectious-Viral	Coronavirus
63	08/2020	Indiana Biosciences Research Institute	BioMEMs Analytics	License	Diagnostic	BioMEMs and SIERRA Reagent to diagnose COVID-19 and other infectious diseases	Link					Yes	PR		Infectious-Viral	Coronavirus	Diagnostics
64	08/2020	Generex Biotechnology	Bintai Kinden	Letter of Intent, License		Ii-Key-SARS-CoV-2 vaccine for COVID-19 in Malaysia	Link					Yes	PR		Infectious-Viral	Coronavirus	Vaccines		Asia
65	08/2020	Therapure	VBI Vaccines	Supply		Manufacture of vaccine drug substance for coronavirus vaccine candidates	Link					Yes	PR		Infectious-Viral	Coronavirus	Vaccines
66	08/2020	Arcturus Therapeutics	Israeli Ministry of Health	Supply		ARCT-021 STARR mRNA vaccine candidate for COVID-19	Link					Yes	PR		Infectious-Viral	Coronavirus	Vaccines		Middle East	ARCT-021, LUNAR-COV19, LUNAR-COVID19	Vaccine	mRNA	2019-nCoV (SARS-CoV-2) (COVID-19)
67	08/2020	George Washington University	Hoth Therapeutics	License, Warrant	Diagnostic, Device	Device to detect the presence of SARS-CoV-2	Link				Yes		SEC Redacted	Exclusive	Infectious-Viral	Coronavirus	Device, Diagnostics		Worldwide																						72.5K warrants @ $2.76/sh, per Hoth's 6Q20 \| mid single-digit royalty, per Hoth's 6Q20
68	08/2020	CytoSorbents	Surgical Partners	Distribution, License	Device	CytoSorb extracorporeal cytokine adsorber for use in COVID-19 patients with respiratory failure	Link					Yes	PR		Infectious-Viral, Respiratory	Coronavirus	Device
69	08/2020	CytoSorbents	InvoSurg	Distribution, License	Device	CytoSorb extracorporeal cytokine adsorber for use in COVID-19 patients with respiratory failure	Link					Yes	PR		Infectious-Viral, Respiratory	Coronavirus	Device
70	08/2020	Coronavirus Immunotherapy Consortium	HiFiBiO	Research	Discovery	Evaluation of neutralizing antibodies against SARS-CoV-2	Link					Yes	PR		Infectious-Viral	Coronavirus	Monoclonals
71	08/2020	Centers for Disease Control, Department of Defense, Department of Health and Human Services	McKesson	Distribution		COVID-19 vaccine distribution to support Operation Warp Speed	Link					Yes	PR		Infectious-Viral	Coronavirus	Vaccines
72	08/2020	Columbia University	IsoPlexis	Research		Single-Cell Secretome immune profiling solutions to advance COVID-19 vaccine development	Link					Yes	PR		Infectious-Viral	Coronavirus	Vaccines
73	08/2020	BioHit Healthcare	ThermoGenesis	Supply	Diagnostic	SARS-CoV-2 IgM/IgG Antibody Test Kit	Link				Yes	Yes	SEC Redacted	Non-exclusive	Infectious-Viral	Coronavirus	Diagnostics
74	08/2020	SK bioscience	Novavax	Supply		Manufacture of antigen component of NVX-CoV2373 COVID-19 vaccine candidate	Link					Yes	PR		Infectious-Viral	Coronavirus	Vaccines			COVID-19 vaccine, NVX-CoV2373	Vaccine	Protein Subunit	2019-nCoV (SARS-CoV-2) (COVID-19)
75	08/2020	TFF Pharmaceuticals	UNION therapeutics	License, Option	Formulation	Thin Film Freezing technology to develop dry powder formulations of niclosamide for COVID-19	Link	210.00				Yes	PR	Exclusive	Infectious-Viral	Coronavirus	Drug Delivery	Other	Worldwide	niclosamide, ANA-001, BAY 2353, NSC-178296, WR 46234	Antiviral		signal transducer and activator of transcription 3 (STAT3)	Inhibitor											210.00						Tiered single-digit royalties \| $210M in development, regulatory and sales milestones
76	08/2020	GenScript Biotech	Beroni Group	Services		CDMO platform to advance study to develop nanobodies to treat COVID-19	Link					Yes	PR		Infectious-Viral	Coronavirus
77	08/2020	Quotient	ANA Therapeutics	Supply		Manufacture of Niclosamide for COVID-19 pivotal clinical trials	Link					Yes	PR		Infectious-Viral	Coronavirus	Synthetics	Small Molecule		niclosamide, ANA-001, BAY 2353, NSC-178296, WR 46234	Antiviral		signal transducer and activator of transcription 3 (STAT3)	Inhibitor
78	08/2020	IsoTherapeutics	NorthStar Medical Radioisotopes, Monopar Therapeutics	Supply		Manufacture of radio-immuno-therapeutic to treat severe COVID-19	Link					Yes	PR		Infectious-Viral	Coronavirus	Monoclonals	Conjugates
79	08/2020	Pfizer	Gilead	Supply	Approved	Manufacture of remdesivir to treat COVID-19	Link					Yes	PR		Infectious-Viral	Coronavirus	Synthetics	Small Molecule		Veklury, remdesivir, GS-5734	Antiviral		replicase polyprotein 1ab, RNA-directed RNA polymerase L	Inhibitor
80	08/2020	ADial Pharmaceuticals	Brik	Distribution	Diagnostic	Rapid Result COVID-19 antibody test kit	Link					Yes	PR		Infectious-Viral	Coronavirus	Diagnostics
81	08/2020	Novavax	Serum Institute of India	Distribution, License, Supply		NVX-CoV2373 COVID-19 vaccine candidate in low- and middle-income countries and India	Link					Yes	PR	Exclusive	Infectious-Viral	Coronavirus	Adjuvant, Vaccines		Asia	COVID-19 vaccine, NVX-CoV2373	Vaccine	Protein Subunit	2019-nCoV (SARS-CoV-2) (COVID-19)
82	08/2020	Aegea Biotechnologies	Biocept	Co-Development, License, Option	Diagnostic	PCR-based COVID-19 assay utilizing Switch-Blocker technology	Link					Yes	PR		Infectious-Viral	Coronavirus	Diagnostics
83	08/2020	Shenzhen Kangtai Biological Products	AstraZeneca	Supply		Manufacture of AZD1222 COVID-19 vaccine	Link					Yes	PR		Infectious-Viral	Coronavirus	Vaccines			COVID-19 vaccine, ChAdOx1, AZD1222	Vaccine	Nonreplicating Viral Vector	2019-nCoV (SARS-CoV-2) (COVID-19)
84	08/2020	Johnson & Johnson, Janssen	Department of Health and Human Services, Department of Defense, BARDA	Supply		100 million doses of Ad26.COV2.S vaccine against COVID-19	Link					Yes	PR		Infectious-Viral	Coronavirus	Vaccines			Ad26.COV2-S, Ad26.COV2.S	Vaccine	Recombinant	2019-nCoV (SARS-CoV-2) (COVID-19)
85	08/2020	BioNTech, Pfizer	Public Health Agency of Canada	Supply	Phase II	BNT162 mRNA-based vaccine candidate against COVID-19	Link					Yes	PR		Infectious-Viral	Coronavirus	Vaccines		NAFTA	BNT162	Vaccine	mRNA	2019-nCoV (SARS-CoV-2) (COVID-19)
86	08/2020	Todos Medical	Pathnova Laboratories	Distribution, License	Diagnostic	COVID-19 and breast cancer tests in Singapore and Southeast Asia	Link					Yes	PR		Cancer, Infectious-Viral	Breast, Coronavirus	Diagnostics		Asia
87	07/2020	Regeneron Pharmaceuticals	Department of Health and Human Services, Department of Defense, BARDA	Supply	Phase II	Manufacture of REGN-COV2 antibody cocktail to treat COVID-19 under Warp Speed Program	Link	450.00				Yes	PR		Infectious-Viral	Coronavirus	Monoclonals			REGN-COV2, REGN-10933+ REGN-10987	Antiviral		2019-nCoV (SARS-CoV-2) (COVID-19)												450.00
88	07/2020	Valneva	UK Government	Supply		60 million doses of VLA2001 SARS-CoV-2 vaccine candidate for COVID-19	Link					Yes	PR		Infectious-Viral	Coronavirus	Adjuvant, Vaccines			VLA2001	Vaccine	Inactivated	2019-nCoV (SARS-CoV-2) (COVID-19)
89	07/2020	Humanetics	NIH, National Institute of Allergy and Infectious Diseases	Research		Funding to support testing of BIO 300 in COVID-19 patients	Link					Yes	PR		Infectious-Viral, Respiratory	Coronavirus				BIO 300, genistein nanoparticle			apoptosis, protein tyrosine kinase (PTK)	Inhibitor
90	07/2020	SmartPharm	Sorrento Therapeutics	Acquisition, Letter of Intent		Acquisition for undisclosed terms	Link					Yes	PR		Cancer, Infectious-Viral	Broad Focus Cancer, Coronavirus
91	07/2020	NIH	Humanigen	CRO	Phase II	Lenzilumab in a COVID clinical trial	Link				Yes	Yes	SEC Full		Infectious-Viral	Coronavirus	Monoclonals			lenzilumab, KB003	Antiviral		colony stimulating factor 2 receptor, alpha, low-affinity (granulocyte-macrophage) (CSF2RA) (GMR) (CD116) (GM-CSF-R-alpha)
92	07/2020	CytoDyn	American Reagent	Distribution	Phase II	PRO140 (leronlimab) for the treatment of COVID-19 in US	Link				Yes		SEC Redacted	Exclusive	Infectious-Viral	Coronavirus	Monoclonals	Humanized Abs	NAFTA	leronlimab, PRO 140, PA-14, WHO 10751, PRO140	Antiviral	anti-CCR5 humanized IgG4 monoclonal antibody inhibitor	CC chemokine receptor type 5 (CCR5) (CD195)	Antagonist
93	07/2020	Emery Pharma	Halodine	CRO		CRO services to support development of oral and nasal antiseptics active against COVID-19	Link					Yes	PR		Infectious-Viral	Coronavirus
94	07/2020	Becton Dickinson	Department of Defense, Department of Health and Human Services	Supply	Diagnostic	Funding to scale up US manufacturing of BD Veritor Solution for Rapid Detection of SARS-CoV-2	Link	24.00				Yes	PR		Infectious-Viral	Coronavirus	Diagnostics																		24.00
95	07/2020	Precipio	ADS Biotec	Distribution	Diagnostic	COVID-19 serology antibody tests	Link					Yes	PR		Infectious-Viral	Coronavirus	Diagnostics
96	07/2020	Medigen Biotech	Alercell	Distribution	Diagnostic	COVID-19 rapid antibody serology tests	Link	280.00				Yes	PR		Infectious-Viral	Coronavirus	Diagnostics																		280.00
97	07/2020	BioNTech, Pfizer	Ministry of Health, Labour and Welfare (Japan)	Supply		120 million doses of BNT162 mRNA-based vaccine candidate against COVID-19	Link					Yes	PR		Infectious-Viral	Coronavirus	Vaccines		Asia	BNT162	Vaccine	mRNA	2019-nCoV (SARS-CoV-2) (COVID-19)
98	07/2020	Intravacc	Celonic AG	Research	Preclinical	COVID-19 vaccine combining immunogenic Spike (S) protein of SARS-CoV-2 and OMV technology	Link					Yes	PR		Infectious-Viral	Coronavirus	Vaccines
99	07/2020	Mesa Biotech	NIH	Development	Diagnostic	Funding to support development of Accula SARS-CoV-2 Test (RADx Program)	Link	15.40				Yes	PR		Infectious-Viral	Coronavirus	Diagnostics																		15.40
100	07/2020	Helix	NIH	Development	Diagnostic	Funding to support rapid scaling of end-to-end COVID-19 test system (RADx Program)	Link	33.40				Yes	PR		Infectious-Viral	Coronavirus	Diagnostics																		33.40